Prevalence of Carbapenem-Resistant *Klebsiella pneumoniae* Infection in a Northern Province in China: Clinical Characteristics, Drug Resistance, and Geographic Distribution

Na Wang¹, Minghua Zhan^{1,2}, Jianhua Liu³, Yao Wang⁴, Yongwang Hou⁵, Caiqing Li¹, Jia Li¹, Xuying Han¹, Jinlu Liu¹, Yong Chen⁶, Jingjing Fan⁶, Jianhua Tang⁷, Wenhua Lu⁸, Xinran Zhong¹, Zhihua Zhang³, Wei Zhang^{1,4}

¹Microbiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, People's Republic of China; ²Clinical Laboratory, Peking University People's Hospital, Beijing, 100730, People's Republic of China; ³Respiratory Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, People's Republic of China; ⁴Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, People's Republic of China; ⁵Clinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, People's Republic of China; ⁶Infectious Disease Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, People's Republic of China; ⁷Clinical Pharmacy Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, People's Republic of China; ⁸Dental Department, Beijing Fengtai Tying Community Health Service Center, Beijing, 100730, People's Republic of China

Correspondence: Wei Zhang; Zhihua Zhang, Tel +86-15369318318, Email 15369318318@163.com; zzh19641229@163.com

Purpose: In this study, we analyzed the clinical distribution and drug resistance of carbapenem-resistant *Klebsiella pneumoniae* (CRKP) strains, the minimum inhibitory concentrations (MIC), MIC50 and MIC90, and geographical distribution in Hebei Province, China. We aimed to provide epidemiological research data, formulate appropriate combined treatment schemes, reasonably select antibiotics, and standardize nosocomial infection control schemes.

Patients and Methods: A total of 6328 strains of CRKP were collected from 2017 to 2019. The MIC was determined for the drug sensitivity test, and the experimental data were statistically analyzed using WHONET5.6.

Results: The detection rate of CRKP increased annually from 13.4% in 2017 to 14.5% in 2018, and 14.6% in 2019. The ratio of males to females was approximately 2:1; 53.6% were elderly, 39% were adults, 4.8% were minors, and 2.5% were newborns. The specimens collected were mainly sputum (70.9%). The resistance rate of CRKP to carbapenems and other β -lactam antibiotics was found to be increasing, with resistance rates generally greater than 90%. The resistance rate to aminoglycoside antibiotics decreased yearly to approximately 50%, and the resistance rate to quinolones remained unchanged at approximately 80%. From 2017 to 2019, the resistance rate of CRKP in Hebei Province to various antibiotics was high, and the resistance rate to β -lactam antibiotics increased each year.

Conclusion: The situation of CRKP resistance is severe in Hebei Province, China. The resistance rate to most antibiotics is very high and shows an upward trend. Among them, the resistance rate to polymyxin is low; however, few resistant strains do exist. MIC50 and MIC90 are higher than their MICs. It mainly causes lung infection in elderly men. This study is helpful to improve the diagnosis, treatment, and prevention of CRKP infection in our province.

Keywords: carbapenems, clinical distribution, drug resistance, minimum inhibitory concentration, geographic distribution, *Klebsiella pneumoniae*

Introduction

Klebsiella pneumoniae is an important bacterium that is normally found in the flora of the human intestinal tract,^{1,2} and is a common microorganism in the environment. It may acquire the carbapenemase-coding, AmpC-producing, or extended-spectrum β -lactamase (ESBLs) with outer membrane porin deletion genes, which leads to carbapenem resistance.³ Carbapenem-coding genes are mostly located on transferable elements such as plasmids or transposons, resulting in the spread of drug-resistant strains.⁴ Bacterial drug resistance has become a major global challenge in the field of public health and is a serious threat to human health. Since the discovery of carbapenem-resistant *K. pneumoniae* (CRKP) in the United States in 1996, carbapenem-resistant *Enterobacteriaceae* (CRE) has spread rapidly worldwide.⁵ In 2019, the US Centers for Disease Control and Prevention listed CRE as an “emergency threat” pathogen threatening human health.

The mortality of patients infected with CRKP is higher than that of carbapenem-sensitive *K. pneumoniae*.⁶ According to the European Antimicrobial Resistance Surveillance Network (EARSN) database, the detection rate of *K. pneumoniae* is higher in Italy than in other European countries.⁷ Globally, the detection rate of CRKP is the highest in Greece (54.9%), followed by eastern Europe (22.5%), Argentina (14%), and the Philippines (11%).⁸ Data from the China Antimicrobial Resistance Surveillance System (CARSS) shows that the national average isolation rate of CRKP increases annually, from 6.4% in 2014 to 10.9% in 2019. The close communication between people all over the world has increased the risk of CRKP transmission.^{9–11}

Tigecycline and polymyxin exhibit a high activity against CRKP.¹² The emergence of new antibiotics such as ceftazidime-avibactam and cefiderocol has resulted in additional treatment options for CRKP infection.^{13–15} Zhang et al¹⁴ reported that the resistance rate of CRKP to ceftazidime-avibactam was only 3.7%. The aim of this study was to determine the distribution of specimens by statistically analyzing regional, sex, and age differences; antimicrobial resistance; minimum inhibitory concentration (MIC) 50/90; geographical distribution; and other aspects of CRKP. The study was conducted to provide epidemiological research data, formulate appropriate combined treatment schemes, reasonably select antibiotics, and standardize nosocomial infection control schemes.

Materials and Methods

Strain Selection and Characteristics

A total of 6328 Clinical CRKP strains were isolated from sputum, blood, secretions, and other specimens of patients between 2017 and 2019. These specimens were collected from 43 tertiary Hospitals in Hebei Province, China. *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as quality control strains. Duplicate strains were removed, and only the first tested sample of the patient was retained. The bacterial drug sensitivity test recommended by Clinical and Laboratory Standards Institute (CLSI) was used, and drug sensitivity was determined using the CLSI drug sensitivity break point of the 2019 edition.

Antimicrobial Susceptibility

Identification and determination of antimicrobial susceptibility of *K. pneumoniae* were performed using the Phoenix 100, FX-200 automatic blood culture instrument (Becton, Dickinson and Company, New Jersey, USA). Blood culture was performed using the BacT/ALERT 3D Microbial Identification System (BIO PARTICIPATIONS Co., LTD, Marcy-l'Étoile, France). MacConkey agar plates (Guangzhou Dijing Microorganism Technology Co., Ltd.) were used to culture and screen the target bacteria.

Susceptibility testing was performed using the minimum inhibitory concentration (MIC) according to Clinical and Laboratory Standards Institute (CLSI, 2019). Isolates with an MIC ≥ 4 mg/L for meropenem and imipenem were defined as CRKP.¹⁶ The stock solution of drugs was prepared and diluted according to the guidelines formulated by Clinical and Laboratory Standards Institute (CLSI). The cultured bacteria to be tested were used to prepare a 0.5 McFarland bacterial suspension. Within 15 min of preparation of the bacterial suspension, 25 μ L of the bacterial suspension and 45 μ L of a colorific indicator were added into the broth and thoroughly mixed. The remaining bacterial suspension was poured into the biochemical well of a BD drug-sensitive plate (Becton, Dickinson and Company, New Jersey, USA), and the solution

Table 1 Distribution Characteristics of CRKP Specimens from 2017 to 2019

Specimen Type	2017 (n = 1516)		2018 (n = 2249)		2019 (n = 2477)		Total	
	N	P (%)	N	P (%)	N	P (%)	N	P (%)
Sputum	1044	68.87	1701	75.63	1738	70.17	4483	70.84
Urine	172	11.35	196	8.71	232	9.37	600	9.48
Blood	93	6.13	124	5.51	138	5.57	355	5.61
Secretion	38	2.51	60	2.67	90	3.63	188	2.97
Ascites	19	1.25	25	1.11	28	1.13	72	1.14
Balf	11	0.73	12	0.53	29	1.17	52	0.82
Bile	12	0.79	16	0.71	20	0.81	48	0.76
Fine needle aspiration	2	0.13	17	0.76	23	0.93	42	0.66
Pus	20	1.32	6	0.27	14	0.57	40	0.63
Drainage	3	0.20	14	0.62	14	0.57	31	0.49
Excreta	10	0.66	21	0.93	11	0.44	42	0.66
Hydrothorax	8	0.53	15	0.67	11	0.44	34	0.54
Other	84	5.54	128	5.48	129	5.21	341	5.39
Total	1516	100	2335	100	2477	100	6328	100.00

Abbreviations: N, number; P, proportion.

in the broth tube was poured into the drug-sensitive well in the drug-sensitive plate. The plate was covered, placed in the Phoenix 100 automated system, cultured for 24 h, and then observed.

Statistical Analysis

Antimicrobial susceptibility data were analyzed with the WHONET 5.6 software (WHO, Geneva, Switzerland). GraphPad prism 8 software (GraphPad Software, LaJolla, CA, USA) was used for drawing, and all counts were expressed as percentages (%).

Results

Specimen Distribution of CRKP

Among the 6328 CRKP isolates, sputum accounted for 4428 (70.9%) isolates, urine accounted for 669 (10.7%) isolates, and blood was the third most common (351 isolates; 5.6%). Secretions accounted for 193 (3.1%) isolates. Ascites accounted for 90 isolates (1.4%), as shown in [Table 1](#).

Geographical Distribution

The geographical distribution remained stable in Hebei Province, from a total of 10 cities counted, and the proportion varied widely. More than 40% of the isolates were from Shijiazhuang, and less than 2% of the isolates were from Langfang as shown in [Table 2](#).

Clinical Data

From 2017 to 2019, the proportion of CRKP, carbapenem-resistant *P. aeruginosa* (CRPae) and carbapenem-resistant *E. coli* (CRECO) in all infected patients and the population were 2.577%, 2.662%, 0.586% and 0.028%, 0.029%, and 0.006% respectively ([Supplementary Table 1](#)); CRKP accounted for 13.4% (1516/11,323), 14.5% (2335/16,100), and 14.6% (2477/16,737) of all isolates of *K. pneumoniae*, respectively. The ratio of males to females was almost unchanged at approximately 2:1, as shown in [Figure 1A](#). The elderly (> 60 years old) accounted for 53.6%, adults (18–60 years old) accounted for 39%, minors (1–18 years old) accounted for 4.84%, and newborns (< 1 year old) accounted for 2.56%. The details are shown in [Figure 1B](#). CRKP was mainly detected in the intensive care unit (ICU) (29.0%), respiratory (15.7%), neurosurgery (14.2%), pediatrics (6.4%), and emergency (3.6%) departments. The details are shown in [Figure 1C](#).

Table 2 Regional Distribution of CRKP in Hebei Province from 2017 to 2019

Territory Name	Year			Total	Proportion (%)
	2017(N)	2018(N)	2019(N)		
Shijiazhuang	891	991	893	2775	43.85
Tangshan	189	525	554	1268	20.04
Cangzhou	76	287	280	643	10.16
Qinhuangdao	89	167	180	436	6.89
Xingtai	94	82	128	304	4.80
Handan	46	66	120	232	3.67
Zhangjiakou	25	110	88	223	3.52
Baoding	63	49	87	199	3.14
Chengde	22	41	99	162	2.56
Langfang	21	17	48	86	1.36
Total	1516	2335	2477	6328	100.00

Abbreviation: N, number.

Drug Susceptibility Analysis

Resistance trend of CRKP to common antibiotics: the resistance of CRKP to cephalosporin antibiotics showed an upward trend, except cefepime, for which the resistance first increased and then decreased. The resistance to penicillin antibiotics (piperacillin) showed an upward trend; the resistance to carbapenem antibiotics, including meropenem and imipenem, showed an upward trend; the resistance to single ring β -lactam antibiotics (aztreonam) increased initially and then decreased; the resistance to β -lactams/ β -lactam inhibitors, including amoxicillin/clavulanate acids and piperacillin/

Figure 1 Overall distribution characteristics of carbapenem-resistant *Klebsiella pneumoniae* (CRKP). (A) Gender distribution characteristics of CRKP. (B) Age distribution characteristics of CRKP. (C) Distribution characteristics of CRKP departments.

Table 3 Drug Sensitivity Data of CRKP to Various Antibacterial Drugs from 2017 to 2019

Antibiotic Name	2017			2018			2019			Average Value		
	N	R(%)	S(%)	N	R(%)	S(%)	N	R(%)	S(%)	N	R (%)	S (%)
Amoxicillin/clavulanic acid	322	80.1	16.8	474	94.9	4.2	593	97.5	1.7	1389	90.8	7.6
Cefotaxime	551	90.4	9.1	809	96.2	3.8	561	95.5	4.1	1921	94.0	5.7
Cefoxitin	647	81.6	15.3	1033	85	10.4	1028	87.2	10.0	2708	84.6	11.9
Piperacillin	1063	97.7	0.9	1308	98.4	0.7	1317	98.8	0.5	3688	98.3	0.7
Tobramycin	833	71.2	22.1	1385	51.3	41.7	1405	56.2	33	3623	59.6	32.3
Aztreonam	1018	93.4	6.4	1513	97.4	2.4	1570	96.4	3.2	4101	95.7	4.0
Cefuroxime	1344	95.8	4.0	1823	97.9	1.8	1733	97.8	2.0	4900	97.2	2.6
Ceftriaxone	1262	95.2	4.7	1840	98.9	0.9	1972	98.7	1.1	5074	97.6	2.2
Compound sulfamethoxazole	1381	68.4	31.4	1875	47.8	52.1	2025	43.8	56.2	5281	53.3	46.6
Cefazolin	1427	91.5	8.5	2213	98.1	1.9	1960	97.8	2.2	5600	95.8	4.2
Amikacin	1507	56.6	42.1	2142	42.7	56.4	2452	43.9	55.5	6101	47.7	51.3
Ciprofloxacin	1439	81.2	13.6	2152	80.3	16.1	2183	84.2	13.7	5774	81.9	14.5
Piperacillin/tazobactam	1504	90.5	6.7	2169	92.9	4.6	2387	94.0	3.9	6060	92.5	5.1
Meropenem	1501	90.7	6.9	2260	94.5	4.4	2219	94.4	4.1	5980	93.2	5.1
Levofloxacin	1491	79.3	17.9	2290	76.8	20.1	2447	81.9	15.4	6228	79.3	17.8
Ceftazidime	1455	92.4	6.7	1981	95.8	3.0	2422	94.1	4.5	5858	94.1	4.7
Gentamicin	1452	71.4	27.1	2303	57.0	40.6	2169	64.5	33.2	5924	64.3	33.6
Imipenem	1510	90.4	7.0	2322	92.0	5.0	2456	94.5	2.9	6288	92.3	5.0
Cefepime	1507	91.8	5.6	2335	92.5	4.9	2462	91.1	4.9	6304	91.8	5.1
Polymyxin	132	0	100	69	1.5	98.5	99	0	100	99	0.5	99.5

Abbreviations: N, number of strains; R, drug resistance rate; S, sensitivity rate.

tazobactam, showed an upward trend. The resistance to aminoglycoside antibiotics including tobramycin, amikacin, and gentamicin showed a downward trend, with the highest decrease observed in the case of tobramycin. The resistance to quinolones, including levofloxacin and ciprofloxacin, showed an upward trend. The resistance to sulfonamides showed a downward trend, with a large decline. In studies from 2017 to 2019, the observed polymyxin resistance rates were 0%, 1.5%, and 0%, respectively, showing a trend of increase at first and then a decrease.

The average resistance rate of CRKP to common antibiotics: the resistance rate to penicillin and β -lactamase/ β -lactamase inhibitors was high: the resistance rate to piperacillin, amoxicillin/clavulanate acid, and piperacillin/tazobactam was 98.3%, 90.8%, and 92.5%, respectively. The resistance rate to cephalosporins was generally high. The resistance rate to First to fourth generation cephalosporins represented by cefazolin, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, and cefepime was 95.8%, 97.2%, 94%, 97.6%, 94.1%, and 91.8%, respectively. The resistance rate to the fourth generation cephalosporins was lower than that to the second and third generation cephalosporins. The resistance rate to carbapenems was relatively high: 92.3% for imipenem and 93.2% for meropenem. The resistance rate to aztreonam was 95.7%; the resistance rate to quinolones was relatively low: 81.9% for ciprofloxacin and 79.3% for levofloxacin. The resistance rate to aminoglycoside antibiotics was relatively low: 59.6% to tobramycin, 47.7% to amikacin, and 64.3% to gentamicin. The resistance rate to cefoxitin was relatively low at 84.6%. The resistance rate to compound sulfamethoxazole antibiotics was low at 53.3%. The average resistance rate to polymyxin was very low, at 0.5% (Table 3).

MIC50 and MIC90

In addition to amikacin, the MIC50 and MIC90 of CRKP was considerably higher than the MICs, and the MIC50 of meropenem, imipenem, and ertapenem was as high as 4 times the drug resistance break point. The MIC50 of cephalosporin antibiotics was 2–16 times the drug resistance break point, and the MIC50 of penicillin and its enzyme inhibitor was equal to its drug resistance break point, as shown in Table 4

Discussion

CRE often causes infection in immunocompromised patients, resulting in prolonged hospital stays and increased mortality.¹⁷ Although there are new antibiotics on the market for CRE infection, it is difficult to overcome antibiotic resistance. This is because there are only a few effective antibiotics and a lack of clinical data, especially data from large randomized controlled clinical research. Therefore, diagnosing, treating, and preventing CRE infection are challenging. It is worth noting that CRKP is listed as a critical-priority bacteria among CREs.¹⁸ The most important resistance mechanism of CRKP involves carbapenemases, and the common ones include *K. pneumoniae* carbapenemases (KPC), New Delhi metallo- β -lactamase (NDM), imipenemase metallo- β -lactamase (IMP), Verona integron-encoded metallo- β -lactamase (VIM), and oxacillinase-48-type carbapenemases (OXA-48).¹⁹ KPC-2 and KPC-3 are the most popular serine carbapenemases. KPC-2 is mainly detected in *K. pneumoniae*. In addition, gram-negative *Enterobacteriaceae* members carrying KPC-2 are resistant to all β -lactamase/ β -lactamase inhibitors, except ceftazidime-avibactam.²⁰ It further increases the limitations of antimicrobial selection and improves mortality. The metalloenzyme does not hydrolyze aztreonam, and the drug sensitivity results are sensitive to aztreonam, but cannot be inactivated or inhibited by avibactam, vaborbactam and relebactam. The strains producing metalloenzyme can be effectively screened using EDTA collaborative experiment. Metalloenzymes encoded by plasmid are a clinical threat because they are located in a mobile genetic structure and can spread and hide resistance genes to other antibiotics.²¹ OXA-48 enzymes are common in *Klebsiella pneumoniae*. They only hydrolyze penicillins and carbapenems, but do not hydrolyze extended spectrum cephalosporins. They often show low-level resistance to carbapenem antibiotics, whereas they are sensitive to the third and fourth generations cephalosporins. Their enzyme activity can be inhibited by avibactam, but cannot be inhibited by vaborbactam and relebactam.²⁰ Therefore, the synergistic effects of different carbapenems may lead to a higher level of resistance to carbapenems and other antibiotics. A study of the characteristics of CRKP is particularly important for controlling pathogens, diagnosing and treating patients.

In recent years, there has been an increasing number of CRKP strains worldwide, but there are some differences in their distributions in different regions.^{8,22} This study showed that CRKP in Hebei Province mainly caused pneumonia, followed by urinary tract infection, bloodstream infection, wound infection, and abdominal infection (Table 1). A study in the United States showed that CRKP strains were mainly derived from urine.²³ However, in Poland, CRKP strains were mainly derived from urine and feces.²⁴ An Italian study showed that CRKP mainly caused urinary tract infections.⁷ A meta-analysis showed that CRKP mainly caused bloodstream infections,⁶ and a study in South Africa showed that 75% of CRKP strains in 2010–2012 were from bloodstream infections.²⁵ CARSS showed that from 2017 to 2019, CRKP accounted for 13.4%, 14.5%, and 14.6%, respectively, showing an upward trend. In addition, data from the China Antimicrobial Surveillance Network (CHINET) indicate that the detection rate of CRKP in China increased from 0.7% in 2007 to 19.9% in 2018.²⁶ However, a New York study showed that the CRKP infection rate in New York City showed a downward trend from 2006 to 2014, especially urinary tract infection.²⁷

The geographical distribution of CRKP is different in Hebei, and its distribution in other cities in China is uneven (Table 2). The latest CARSS data showed that Henan, Shanghai, and Beijing were the top three cities in the national CRKP separation rate in 2019, and Qinghai and Tibet were the least. Hu et al²⁸ calculated the separation rate of CRKP in various regions of China, and the separation rates in Inner Mongolia, Guangxi, Shanxi, Heilongjiang, Hainan, Gansu, Jilin, Ningxia, Qinghai, and Tibet were less than 5%, those in Jiangsu, Anhui, Jiangxi, Liaoning, Hebei, Hubei, Zhejiang, Yunnan, and Hunan were 10% to 20%, those in Beijing, Shanghai, and Henan were more than 20%. It was observed that CRKP distribution is related to the population distribution in China. The distribution of CRKP is greater in areas with larger populations and more developed economies, and less in areas with smaller populations and less developed economies. However, in contrast to the conclusion of this study, the detection rate of CRKP in underdeveloped countries such as Greece, Argentina, and the Philippines is much higher than that in developed countries all over the world.⁸ In this study, there were twice as many males as females with CRKP infection. A study in Taiwan²⁹ compared the mortality rate of patients with urinary tract infections caused by CRKP, with a higher level of infection among males than females. Analysis from the age of the patient, we found that elderly patients in Hebei Province were the most important CRKP group, which is common across China and the world.^{22,30} Patients with CRKP infection in our province are mainly in

ICU, which agrees with previously reported findings in HeBei Province.¹⁶ In Ireland, CRKP infection is mainly concentrated in ICU and surgical ward.²⁴ A study from Egypt showed that CRKP was mainly separated from the surgical ICU.³¹

The treatment of CRKP infection remains an intractable problem in clinics.^{7,32} The resistance rate of CRKP to penicillin and penicillin with β -lactamase inhibitors, especially to amoxicillin/clavulanic acid, is increasing yearly (Table 3). Amoxicillin/clavulanic acid is a commonly used antibiotic in pediatrics, and piperacillin/tazobactam is commonly used for the empirical treatment of nosocomial infection.^{33,34} Clavulanic acid and tazobactam mainly inhibit the activity of serine- β -lactamases, including CTX-M β -lactamases and the ESBL derivatives TEM-1, TEM-2, and SHV-1.²⁰ The wide clinical use and limited drug action of these drugs lead to a high drug resistance rate. In our province, the resistance rate of CRKP to carbapenems is high and increasing yearly. CRKP is resistant to a variety of antibiotics, leading to a limited choice of therapeutic drugs. Treatment options for CRKP infection include the classic polymyxin, tigecycline, aminoglycosides, fosfomycin, a few quinolones or sulfonamides, and new drugs β -lactamase/ β -lactamase inhibitors. Tigecycline and colistin are optional drugs for the treatment of CRKP; however, unfortunately, there are strains resistant to them.³² In 2004, a CRKP strain resistant to polymyxin was first reported in Greece.²³ Since then, additional reports show that CRKP strains resistant to polymyxin have been isolated in a Hospital environment.³⁵ From 2009 to 2018, the rate of resistance of CRKP to fosfomycin in China decreased from 81.8% to 50.8%, while that to tigecycline increased from 3.8% to 21.7%, and that to polymyxin B increased from 1.6% in 2013 to 18.3% in 2017.²⁶ Fosfomycin inhibits the synthesis of bacterial cell walls and shows synergistic effects when combined with a variety of antibiotics. The drug is mainly excreted from the kidney in its original form and is highly concentrated in the urine. Oral administration of fosfomycin is mainly used to treat urinary tract infections. In Hebei Province, the resistance rate to polymyxin was 0.5%, and only a few drug-resistant strains emerged in 2018. The use of polymyxin is associated with several challenges, including high-dose nephrotoxicity and drug resistance. In the study of synergism between polymyxin and carbapenems, polymyxin exerted a synergistic effect on 50% of carbapenems.³⁶ A meta-analysis showed³⁷ that the mortality of patients on polymyxin/tigecycline and polymyxin/carbapenem combination therapy was lower than that of patients on polymyxin alone; polymyxin alone is not recommended in routine clinical practice. The polymyxin-resistant CRKP strain was less sensitive to amikacin and tigecycline, but more sensitive to gentamicin.²³ Therefore, polymyxin can be combined with gentamicin and carbapenem for the treatment of CRKP infection. Polymyxin E methanesulfonate (CMS) is recommended for the treatment of CRE urinary tract infection because of its high colistin concentration in the urine. Tigecycline is a time-dependent drug with a long post-antibiotic effect. The drug level after intake is relatively low in the blood and cerebrospinal fluid,³⁸ and therefore, it is not routinely recommended for CRKP-induced bloodstream infections and central nervous system infections. A systematic retrospective study found that increasing the dose of tigecycline can improve the clinical efficiency and microbial clearance in the treatment of hospital-acquired pneumonia (HAP). In addition, the mortality of tigecycline alone was higher than that of combined use.³⁹ It is recommended to combine tigecycline with two or three drugs. The resistance rate of CRKP to cephalosporins in Hebei Province showed an increasing trend (Table 3). The resistance rates to ceftriaxone and cefuroxime were close to 100%. The resistance rate to cefepime was slightly lower than that of the second and third generation cephalosporins. El Badawy et al³¹ showed that clinically isolated CRKP was 100% resistant to cefazolin, cefradine, cefoperazone, and cefotaxime. In this study, it was also found that among the quinolones, levofloxacin was better than ciprofloxacin. Notably, the rate of resistance of CRKP to sulfamethoxazole in our province decreased (similar to the CHINET data²⁶); similarly, the rate of resistance to amikacin also reduced. An et al⁴⁰ showed that CRKP had the lowest rate of resistance to amikacin. The resistance rate to tobramycin and gentamicin was maintained at approximately 60%, which was lower than that of β -lactam antibiotics. A multivariate study showed that the treatment of CRKP infection with gentamicin (MIC $\leq$ 2 mg/L) was associated with a lower mortality of patients.⁴¹ Van Duin et al reported that amikacin was effective against 83% of CRKP⁴² cases. Aminoglycoside antibiotics exhibit more efficient microbial clearance in urinary tract infections caused by CRKP.⁴³ In our province, aminoglycoside antibiotics is empirically applied to treat CRKP infection. In Hebei Province, the resistance rate of CRKP to sulfamethoxazole is low, which is consistent with the results of He et al and Lombardi.^{44,45} A recent study found that in vitro, compound sulfamethoxazole combined with polymyxin can quickly kill clinically isolated CRKP within 2–24 h, but this result needs further evidence-based medicine and clinical research certification.⁴⁶ From 2017 to 2019, the MIC50/MIC90 of CRKP to imipenem and meropenem in Hebei Province

Table 4 CRKP MIC50 and MIC90 of CRKP

Projects	Quantity	Break Point	MIC50	MIC90	MIC Range
Tigecycline	962	S≤0.03 R≥0.25	0.5	2	0.02–64
Compound sulfamethoxazole	4978	S≤2 R≥4	4	16	0.25–128
Ciprofloxacin	5430	S≤1 R≥4a	4	8	0.01–64
Etapenan	724	S≤0.5 R≥2	8	16	0.25–64
Levofloxacin	5646	S≤2 R≥8	8	16	0.06–64
Tobramycin	3546	S≤4 R≥16	16	16	0.5–32
Meropenem	5359	S≤1 R≥4	16	32	0.06–128
Gentamicin	5370	S≤4 R≥16	16	16	0.5–32
Amikacin	5479	S≤16 R≥64	16	64	1–128
Imipenem	5658	S≤1 R≥4	16	32	0.12–64
Amoxicillin/clavulanic acid	1027	S≤8 R≥32	32	32	0.5–64
Cefoxitin	2218	S≤8 R≥32	32	64	1–128
Cefepime	5694	S≤2 R≥16	32	64	0.12–128
Cefotaxime	1327	S≤1 R≥4	64	64	0.12–128
Aztreonam	3738	S≤4 R≥16	64	128	0.25–128
Cefuroxime	4528	S≤8 R≥32	64	128	1–128
Ceftriaxone	4624	S≤1 R≥4	64	128	0.12–128
Cefazolin	5074	S≤16 R≥32	64	128	1–128
Ceftazidime	5364	S≤4 R≥16	64	64	0.06–128
Piperacillin	3414	S≤16 R≥128	128	256	2–256
Piperacillin/tazobactam	5643	S≤16 R≥128	128	256	0.5–256

Note: MIC50/MIC90, MIC50 and MIC90 can inhibit 50% or 90% of the tested bacteria.

Abbreviation: MIC, minimum inhibitory concentration.

was 16/32 µg/mL (Table 4). Studies have found that when the MIC of meropenem is ≤8 mg/L, adding a large dose of meropenem (2 g once every 8 h) to another active drug can reduce the mortality of patients with CRE infection.³⁶ If the MIC of the strain to carbapenems is > 8 mg/L, the combination regimen containing carbapenems is no longer recommended. In China, from 2007 to 2018, the MIC90 of CRKP to imipenem fluctuated between 32 and 256, and the MIC90 for meropenem increased from 64 in 2009 to 256 in 2018.²⁶ Studies have shown that the use of carbapenem is an independent risk factor for CRKP infection,^{47,48} and therefore, clinicians should use carbapenem antibiotics cautiously to reduce the risk of CRKP infection. Recent reports from Europe, Canada, the United States, Asia, and Africa show that CRKP is spreading worldwide.⁴⁹ Based on the increasing trend of the CRKP detection rate worldwide, the prevalence of CRKP needs to be studied in a global context to understand its transmission rules and to provide data support for the development of prevention and control measures.

Conclusion

In summary, from 2017 to 2019, in Hebei Province, CRKP primarily caused lung infection; males accounted for about two-thirds, and older patients represented the majority of the patient population. Regional distribution varied greatly and was mainly concentrated in the economically developed and populous cities such as Shijiazhuang and Tangshan. The resistance rate of CRKP to β-lactam antibiotics was higher than 90%, and it is increasing annually. The resistance rate to sulfamethoxazole and aminoglycoside antibiotics was lower than 70%, showing a downward trend annually, and MIC50/MIC90 was higher for all kinds of antibacterial drugs. Antibiotics should be selected according to the results of drug sensitivity tests for the clinical treatment of CRKP infection, and positive and effective isolation measures should be taken to reduce the risk of nosocomial infection. This retrospective study was performed to analyze the clinical characteristics and the results of susceptibility testing of CRKP in Hebei Province, China, which has the advantage of broad coverage and large sample sizes. Hence, it can accurately reflect the current situation of CRKP infection in Hebei Province, provide epidemiological data for future clinical prevention and treatment, reduce the infection rate, and improve the success rate of the treatment of CRKP infection. The current study was performed using data of small

number of samples, and the representativeness may be biased. In order to solve the above problem, we collected 6328 CRKP samples. A limitation of this study is that there is no genotyping of CRKP, and the link between the strains cannot be constructed. Therefore, advanced monitoring of the changes in CRKP resistance mechanism is required in the future. Considering that CRKP is highly resistant to commonly used antibiotics, attention should be paid to the training and assessment of clinicians on the rational use of antibiotics to reduce the infection rate of multidrug-resistant bacteria in the future.

Data Sharing Statement

The data used and/or analyzed in this study are available from the corresponding author on reasonable request.

Ethics Approval and Informed Consent

The protocol has been reviewed by the Ethics Committee (IRB) of the First Affiliated Hospital of Hebei North University. As this was an observational study and strains cultured from residual samples were used in clinical diagnosis, the confidentiality of patient data is preserved and compliance with the Declaration of Helsinki is ensured. As the data did not affect patient care, the exemption criteria were met. After consulting the IRB of the First Affiliated Hospital of Hebei North University, a formal ethical review approval was obtained; written informed consent from the patient was not required (ethical approval no.: K2019147).

Acknowledgments

We thank Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College and Clinical Laboratory, and Laboratory of Peking University People's Hospital for administrative and technical support. Many thanks to graduate students Zhan Xuli, Yue Weiye, Si Liyan, Yang Zhicong, Li Jingqi and Wang Yuandi for their contributions to the preservation of strains. The author thanks Editage (www.editage.cn) for English language editing.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding

This work was supported by National Key R & D Plan Research on Standardized Diagnosis, Investigation and Treatment Technology System of New and Major Foodborne Diseases (2017YFC1601502), Scientific Research Fund Project of Hebei Provincial Health Commission (20180843, 20190904, and 20210702) and Key R&D project of Zhangjiakou City (2121098D, 2121064D).

Disclosure

The authors report no conflicts of interest in relation to this study.

References

1. Zhu J, Wang T, Chen L, Du H. Virulence factors in hypervirulent *Klebsiella pneumoniae*. *Front Microbiol.* 2021;12:642484. doi:10.3389/fmicb.2021.642484
2. Martin RM, Bachman MA. Colonization, Infection, and the accessory genome of *Klebsiella pneumoniae*. *Front Cell Infect Microbiol.* 2018;8:4. doi:10.3389/fcimb.2018.00004
3. Di Tella D, Tamburro M, Guerrizio G, Fanelli I, Sammarco ML, Ripabelli G. Molecular epidemiological insights into colistin-resistant and carbapenemases-producing clinical *Klebsiella pneumoniae* isolates. *Infect Drug Resist.* 2019;12:3783–3795. doi:10.2147/IDR.S226416
4. Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. *Expert Rev Anti Infect Ther.* 2014;12(5):565–580. doi:10.1586/14787210.2014.902306
5. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2001;45(4):1151–1161. doi:10.1128/AAC.45.4.1151-1161.2001

6. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant *Klebsiella pneumoniae*. *Ann Clin Microbiol Antimicrob*. 2017;16(1):18. doi:10.1186/s12941-017-0191-3
7. Barbadoro P, Dichiaro A, Arsego D, et al. Spread of carbapenem-resistant *Klebsiella pneumoniae* in hub and spoke connected health-care networks: a case study from Italy. *Microorganisms*. 2019;8(1):37. doi:10.3390/microorganisms8010037
8. Diallo OO, Baron SA, Abat C, Colson P, Chaudet H, Rolain JM. Antibiotic resistance surveillance systems: a review. *J Glob Antimicrob Resist*. 2020;23:430–438. doi:10.1016/j.jgar.2020.10.009
9. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection and the impact of antimicrobial and adjunctive therapies. *Infect Control Hosp Epidemiol*. 2008;29(12):1099–1106. doi:10.1086/592412
10. Grundmann H, Glasner C, Albiger B, et al. Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *Lancet Infect Dis*. 2017;17(2):153–163. doi:10.1016/S1473-3099(16)30257-2
11. Zhang R, Chan EW, Zhou H, Chen S. Prevalence and genetic characteristics of carbapenem-resistant Enterobacteriaceae strains in China. *Lancet Infect Dis*. 2017;17(3):256–257. doi:10.1016/S1473-3099(17)30072-5
12. Yu L, Zhang J, Fu Y, et al. Synergetic effects of combined treatment of colistin with meropenem or amikacin on carbapenem-resistant *Klebsiella pneumoniae* in vitro. *Front Cell Infect Microbiol*. 2019;9:422. doi:10.3389/fcimb.2019.00422
13. Liao W, Liu Y, Zhang W. Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant *Klebsiella pneumoniae* in China: a review over the last 10 years. *J Glob Antimicrob Resist*. 2020;23:174–180. doi:10.1016/j.jgar.2020.09.004
14. Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant *Klebsiella pneumoniae* in China. *Clin Microb Infect*. 2020;26(1):124.e124–124.e124. doi:10.1016/j.cmi.2019.08.020
15. Matsumoto S, Singley CM, Hoover J, et al. Efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. *Antimicrob Agents Chemother*. 2017;61(9). doi:10.1128/AAC.00700-17.
16. Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection in a tertiary hospital in North China. *Antimicrob Resist Infect Control*. 2020;9(1):79. doi:10.1186/s13756-020-00728-3
17. Tzouvelekis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella pneumoniae* and other Enterobacteriaceae: an evolving crisis of global dimensions. *Clin Microbiol Rev*. 2012;25(4):682–707. doi:10.1128/CMR.05035-11
18. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
19. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis*. 2011;17(10):1791–1798. doi:10.3201/eid1710.110655
20. Bush K, Bradford PA. Interplay between β -lactamases and new β -lactamase inhibitors. *Nat Rev Microbiol*. 2019;17(5):295–306. doi:10.1038/s41579-019-0159-8
21. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev*. 2007;20(3):440–458, table of contents. doi:10.1128/CMR.00001-07
22. Hu Y, Liu C, Shen Z, et al. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant *Klebsiella pneumoniae* in patients from Zhejiang, China, 2008–2018. *Emerg Microbes Infect*. 2020;9(1):1771–1779. doi:10.1080/22221751.2020.1799721
23. Rojas LJ, Salim M, Cober E, et al. Colistin resistance in carbapenem-resistant *Klebsiella pneumoniae*: laboratory detection and impact on mortality. *Clin Infect Dis*. 2017;64(6):711–718. doi:10.1093/cid/ciw805
24. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis*. 2013;13(9):785–796. doi:10.1016/S1473-3099(13)70190-7
25. Malinga NZZ, Shobo CO, Molechan C, Amoako DG, Zishiri OT, Bester LA. Molecular surveillance and dissemination of *Klebsiella pneumoniae* on frequently encountered surfaces in South African Public Hospitals. *Microb Drug Resist*. 2021. doi:10.1089/mdr.2020.0546
26. Gao L, Lv Y, Li Y. Analysis of the drug resistance of carbapenem-resistant *Klebsiella pneumoniae* in the China antimicrobial resistance surveillance trial program, 2007–2018. *Microb Drug Resist*. 2020;26(8):944–950. doi:10.1089/mdr.2019.0299
27. Park SO, Liu J, Furuya EY, Larson EL. Carbapenem-resistant *Klebsiella pneumoniae* infection in three New York City Hospitals Trended downwards from 2006 to 2014. *Open Forum Infect Dis*. 2016;3(4):ofw222. doi:10.1093/ofid/ofw222
28. Hu F, Zhu D, Wang F, Wang M. Current status and trends of antibacterial resistance in China. *Clin Infect Dis*. 2018;67(suppl_2):S128–S134. doi:10.1093/cid/ciy657
29. Chuang C, Su CF, Lin JC, et al. Does antimicrobial therapy affect mortality of patients with carbapenem-resistant *Klebsiella pneumoniae* bacteriuria? A nationwide multicenter study in Taiwan. *Microorganisms*. 2020;8(12):2035. doi:10.3390/microorganisms8122035
30. Li J, Li Y, Song N, Chen Y. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* infection: a meta-analysis. *J Glob Antimicrob Resist*. 2020;21:306–313. doi:10.1016/j.jgar.2019.09.006
31. El-Badawy MF, El-Far SW, Althobaiti SS, Abou-Elazm FI, Shohayeb MM. The First Egyptian report showing the co-existence of bla (NDM-25), bla (OXA-23), bla (OXA-181), and bla (GES-1) among carbapenem-resistant *K. pneumoniae* clinical isolates genotyped by BOX-PCR. *Infect Drug Resist*. 2020;13:1237–1250. doi:10.2147/IDR.S244064
32. Zhang R, Dong N, Huang Y, et al. Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant *Klebsiella pneumoniae*) in vivo and its persistence in the GI tract. *Emerg Microbes Infect*. 2018;7(1):127. doi:10.1038/s41426-018-0129-7
33. Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T. Comparison of antipseudomonal β -lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. *Clin Microb Infect*. 2017;23(10):723–729. doi:10.1016/j.cmi.2017.03.024
34. Nimmich EB, Bookstaver PB, Kohn J, et al. Development of institutional guidelines for management of gram-negative bloodstream infections: incorporating local evidence. *Hosp Pharm*. 2017;52(10):691–697. doi:10.1177/0018578717720506
35. Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem-resistant *Klebsiella pneumoniae* in metropolitan Detroit, Michigan. *Antimicrob Agents Chemother*. 2011;55(2):593–599. doi:10.1128/AAC.01020-10
36. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. *Clin Microbiol Rev*. 2018;31(2). doi:10.1128/CMR.00079-17

37. Hou SY, Wu D, Feng XH. Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant *Klebsiella pneumoniae*: a systematic review and meta-analysis. *J Glob Antimicrob Resist*. 2020;23:197–202. doi:10.1016/j.jgar.2020.08.024
38. Peterson LR. A review of tigecycline—the first glycylcycline. *Int J Antimicrob Agents*. 2008;32(Suppl 4):S215–222. doi:10.1016/S0924-8579(09)70005-6
39. Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. *Medicine*. 2016;95(11):e3126. doi:10.1097/MD.00000000000003126
40. An X, Xie W, Zheng X, Zhao L, Wu Y, Qu Y. [Detection and analysis of carbapenem-resistant *Klebsiella pneumoniae* resistance genes in five hospitals in Qingdao City]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. 2020;32(2):145–149. Chinese. doi:10.3760/cma.j.cn121430-20200110-00027
41. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother*. 2015;70(3):905–913. doi:10.1093/jac/dku432
42. van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother*. 2015;70(4):1203–1211. doi:10.1093/jac/dku495
43. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant *Klebsiella pneumoniae* from urine. *Antimicrob Agents Chemother*. 2011;55(12):5893–5899. doi:10.1128/AAC.00387-11
44. He G, Huang J, Huang S, et al. Risk factors affecting clinical outcome in patients with carbapenem-resistant *K. pneumoniae*: a retrospective study. *Med Sci Monitor*. 2020;26:e925693. doi:10.12659/MSM.925693
45. Lombardi F, Gaia P, Valaperta R, et al. Emergence of carbapenem-resistant *Klebsiella pneumoniae*: progressive spread and four-year period of observation in a cardiac surgery division. *Biomed Res Int*. 2015;2015:871947. doi:10.1155/2015/871947
46. Su J, Li D, Guo Q, Guo Y, Zheng Y, Xu X. In vitro bactericidal activity of trimethoprim-sulfamethoxazole/colistin combination against carbapenem-resistant *Klebsiella pneumoniae* clinical isolates. *Microb Drug Resist*. 2019;25(2):152–156. doi:10.1089/mdr.2018.0085
47. Gagliotti C, Giordani S, Ciccarese V, et al. Risk factors for colonization with carbapenemase-producing *Klebsiella pneumoniae* in hospital: a matched case-control study. *Am J Infect Control*. 2014;42(9):1006–1008. doi:10.1016/j.ajic.2014.05.028
48. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant *Acinetobacter baumannii*: a case-control study. *Antimicrob Agents Chemother*. 2004;48(1):224–228. doi:10.1128/AAC.48.1.224-228.2004
49. Navon-Venezia S, Kondratyeva K, Carattoli A. *Klebsiella pneumoniae*: a major worldwide source and shuttle for antibiotic resistance. *FEMS Microbiol Rev*. 2017;41(3):252–275. doi:10.1093/femsre/fux013

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>